World journal of emergency surgery : WJES · 2025
Early fluid therapy trajectories in acute pancreatitis: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wan Jianhua, Xiong Shixuan, Zou Yaoyu, Kuang Maobin, Ke Huajing, He Wenhua, Zhu Yin, Lu Nonghua, Xia Liang
Аннотация
BACKGROUND: Individualized management of early fluid therapy in acute pancreatitis (AP) remains challenging. Traditional studies primarily focus on static fluid balance, overlooking the heterogeneity of dynamic trajectories.
METHODS: Based on a single-center retrospective cohort, 3,142 AP patients admitted within 72 h of onset were included. Daily fluid therapy-to-body weight ratio (FWR) and CumFWR (trapezoidal AUC) were calculated. Latent Class Growth Modeling (LCGM) identified dynamic FWR trajectories within 72 h. Multivariate Cox regression analyzed the relationship between FWR and in-hospital mortality risk. Three-dimensional fitted surface plot analysis evaluated interactions between CumFWR and hematocrit.
RESULTS: LCGM successfully identified five distinct dynamic fluid therapy trajectories within 72 h, showing significant clinical differences: Low Stable Group (LSG1, n = 229, 7.3%), Low-Moderate Sustained Group (LMSG2, n = 340, 10.8%), Moderate Stable Group (MSG3, n = 2073, 66.0%), Moderate-High Fluctuating Group (MHFG4, n = 231, 7.4%), and High Sustained Group (HSG5, n = 269, 8.6%). Multivariate Cox regression revealed significantly increased in-hospital mortality risk compared to MSG3 for both MHFG4 (adjusted HR = 2.08, 95%CI 1.15-3.78) and HSG5 (adjusted HR = 2.91, 95%CI 1.77-4.79). Furthermore, each 1 standard deviation increase in CumFWR was associated with a 47% increased mortality risk (HR = 1.47, 95%CI 1.26-1.72). Three-dimensional fitted surface plot demonstrated high mortality risk between high CumFWR and abnormal hematocrit (low/high HCT), particularly prominent in the HSG5 group (p < 0.001).
CONCLUSION: This study reveals five distinct dynamic trajectory patterns of early fluid therapy in AP. High-load sustained or fluctuating therapy significantly increases mortality risk. Dynamic monitoring of HCT (within a 35-44% safety window) and therapy trajectories offers a potential strategy to optimize fluid management.
METHODS: Based on a single-center retrospective cohort, 3,142 AP patients admitted within 72 h of onset were included. Daily fluid therapy-to-body weight ratio (FWR) and CumFWR (trapezoidal AUC) were calculated. Latent Class Growth Modeling (LCGM) identified dynamic FWR trajectories within 72 h. Multivariate Cox regression analyzed the relationship between FWR and in-hospital mortality risk. Three-dimensional fitted surface plot analysis evaluated interactions between CumFWR and hematocrit.
RESULTS: LCGM successfully identified five distinct dynamic fluid therapy trajectories within 72 h, showing significant clinical differences: Low Stable Group (LSG1, n = 229, 7.3%), Low-Moderate Sustained Group (LMSG2, n = 340, 10.8%), Moderate Stable Group (MSG3, n = 2073, 66.0%), Moderate-High Fluctuating Group (MHFG4, n = 231, 7.4%), and High Sustained Group (HSG5, n = 269, 8.6%). Multivariate Cox regression revealed significantly increased in-hospital mortality risk compared to MSG3 for both MHFG4 (adjusted HR = 2.08, 95%CI 1.15-3.78) and HSG5 (adjusted HR = 2.91, 95%CI 1.77-4.79). Furthermore, each 1 standard deviation increase in CumFWR was associated with a 47% increased mortality risk (HR = 1.47, 95%CI 1.26-1.72). Three-dimensional fitted surface plot demonstrated high mortality risk between high CumFWR and abnormal hematocrit (low/high HCT), particularly prominent in the HSG5 group (p < 0.001).
CONCLUSION: This study reveals five distinct dynamic trajectory patterns of early fluid therapy in AP. High-load sustained or fluctuating therapy significantly increases mortality risk. Dynamic monitoring of HCT (within a 35-44% safety window) and therapy trajectories offers a potential strategy to optimize fluid management.